» Articles » PMID: 35811988

Diet Containing Soy Protein Concentrate With Low and High Isoflavones for 9 Weeks Protects Against Non-alcoholic Fatty Liver Steatosis Using Obese Zucker Rats

Overview
Journal Front Nutr
Date 2022 Jul 11
PMID 35811988
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic fatty liver disease (NAFLD), is one of the main liver diseases in the US and the world which often is related to obesity. Previously, we reported short- and long-term consumption of soy protein isolate diet with high isoflavones can reduce liver steatosis in the male and female obese Zucker rat model. However, the effects of high vs. low soy isoflavones on NAFLD is less known. The objectives of the present study were to examine the role of isoflavones levels in soy protein concentrate diets on protection against NAFLD in an obese rat model. Forty-two 6-week old lean (L, = 21) and obese (O, = 21) Zucker rats were randomly assigned to 1 of 3 dietary groups: casein diet (C = control), soy protein concentrate with low isoflavones (LIF), or soy protein concentrate with high isoflavones (HIF) for 9 weeks. Rats were weighed twice weekly. After 9 weeks, rats were sacrificed and samples of livers were taken for histopathological analysis. Serums were collected to measure ALT and AST levels. Results indicate that obese rats gained significantly more weight than lean rats for all three diet groups ( < 0.001). No significant difference in body weight between LC, LLIF and LHIF was noted. However, the OLIF and OHIF rats gained significantly more weight than OC rats ( < 0.001). Liver steatosis scores were significantly greater in obese rats compared to lean rats ( < 0.001). The OLIF and OHIF-fed rats had significantly reduced steatosis scores than OC rats ( = 0.013 and < 0.001, respectively). The serum ALT levels were significantly greater in OC, OLIF and OHIF compared to LC, LLIF and LHIF, respectively ( < 0.001, < 0.001, and = 0.011). AST serum levels were greater in OC and OLIF compared to LC and LLIF, respectively ( = 0.001 and = 0.022). In summary, we found that soy protein concentrate with isoflavones protects against liver steatosis and the protection is greater with a higher concentration of isoflavones.

Citing Articles

Dietary soy protein reverses obesity-induced liver steatosis and alters fecal microbial composition independent of isoflavone level.

Hakkak R, Korourian S, Li W, Spray B, Twaddle N, Randolph C Front Nutr. 2024; 11:1487859.

PMID: 39529929 PMC: 11551038. DOI: 10.3389/fnut.2024.1487859.


Soy Protein Concentrate Diets Inversely Affect LPS-Binding Protein Expression in Colon and Liver, Reduce Liver Inflammation, and Increase Fecal LPS Excretion in Obese Zucker Rats.

Li W, Hakkak R Nutrients. 2024; 16(7).

PMID: 38613016 PMC: 11013665. DOI: 10.3390/nu16070982.


The effect of soy isoflavones on non-alcoholic fatty liver disease and the level of fibroblast growth factor-21 and fetuin A.

Neshatbini Tehrani A, Hatami B, Helli B, Yari Z, Daftari G, Salehpour A Sci Rep. 2024; 14(1):5134.

PMID: 38429385 PMC: 10907727. DOI: 10.1038/s41598-024-55747-6.


Feeding soy protein concentrates with low or high isoflavone decreases liver inflammation by reducing lipopolysaccharide translocation.

Li W, Hakkak R Front Nutr. 2023; 10:1278158.

PMID: 38075211 PMC: 10699199. DOI: 10.3389/fnut.2023.1278158.


The Role of Choline, Soy Isoflavones, and Probiotics as Adjuvant Treatments in the Prevention and Management of NAFLD in Postmenopausal Women.

DiStefano J Nutrients. 2023; 15(12).

PMID: 37375574 PMC: 10304350. DOI: 10.3390/nu15122670.


References
1.
Bray G . The Zucker-fatty rat: a review. Fed Proc. 1977; 36(2):148-53. View

2.
Aleixandre de Artinano A, Miguel Castro M . Experimental rat models to study the metabolic syndrome. Br J Nutr. 2009; 102(9):1246-53. DOI: 10.1017/S0007114509990729. View

3.
Kim M, Park J, Jung J, Byun K, Kang K, Lee Y . Daidzein supplementation prevents non-alcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism. Int J Obes (Lond). 2010; 35(8):1019-30. DOI: 10.1038/ijo.2010.256. View

4.
Liu H, Zhong H, Leng L, Jiang Z . Effects of soy isoflavone on hepatic steatosis in high fat-induced rats. J Clin Biochem Nutr. 2017; 61(2):85-90. PMC: 5612816. DOI: 10.3164/jcbn.16-98. View

5.
Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View